Skip to main content

MicroRNA Start-up Rosetta Genomics Closes $4M Private Equity Round

NEW YORK, March 28 (GenomeWeb News) - Israeli microRNAi-technology start-up Rosetta Genomics has closed a $4-million financing round recently, according to a news report.


Rosetta has developed a way to discover microRNA genes, and hopes to begin generating revenue in 2006, according to Globes Online. The current financing round will help the company expand its IP estate and pay for clinical trials on animals for the miniature molecules it has developed.


The round, Rosetta's third, was led by Kadima High Tech. Other investors included Israeli drug maker Teva Pharmaceuticals; Leon Recanati; GlenRock Israel; VCON Chairman and CEO Yair Shamir; Agis chairman Moshe Arkin; Uzia Galil; Yoav Chelouche of the Fantine Group; Nathan Hod, former CEO of DSP Communications; Mordechai Segal, cofounder of Libit Signal Processing; Ami Lidor of Lidor Chemicals; Moshe Many, former president of Tel Aviv University, and chairman of Teva's R&D committee; Michael Sela, Israel Prize laureate and former president of the Weizmann Institute of Science; First International Bank of Israel Chairman Joshua Rosensweig; Ehud Arad of the law firm Bach, Arad, Scharf, & Co.; and investor Michael Davis.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.